抑郁症与阿片受体及其表观遗传调控
摘要
阿片受体是一类重要的G蛋白偶联受体,阿片受体在神经系统中分布广泛,在疼痛和成瘾的神经生物学过程中起着重要作用。研究表明阿片受体及其表观遗传调控在情绪调节中发挥重要作用。μ阿片受体(MOR)激动剂作为抗抑郁药已用于临床,且δ阿片受体(DOR)激动剂和κ阿片受体(KOR)拮抗剂也具有极大的抗抑郁潜能。本文主要阐述阿片受体的表观遗传调控,并阐明其与抑郁症的相关性,为抑郁症个体化预防和治疗策略提供新方向。
引文
[1]Vandeleur CL,Fassassi S,Castelao E,et al.Prevalence and correlates of DSM-5 major depressive and related disorders in the community[J].Psychiatry Res,2017,250:50-58.
[2]Arroll B,Elley CR,Fishman T,et al.Antidepressants versus placebo for depression in primary care[J].Cochrane Database Syst Rev,2009,3:D7954.
[3]Tenore PL.Psychotherapeutic benefits of opioid agonist therapy[J].JAddict Dis,2008,27:49-65.
[4]Machado-Vieira R,Zarate C J.Proof of concept trials in bipolar disorder and major depressive disorder:a translational perspective in the search for improved treatments[J].Depress Anxiety,2011,28:267-281.
[5]Munoa I,Urizar I,Casis L,et al.The epigenetic regulation of the opioid system:new individualized prompt prevention and treatment strategies[J].J Cell Biochem,2015,116:2419-2426.
[6]Evans CJ,Keith DJ,Morrison H,et al.Cloning of a delta opioid receptor by functional expression[J].Science,1992,258:1952-1955.
[7]Yasuda K,Raynor K,Kong H,et al.Cloning and functional comparison of kappa and delta opioid receptors from mouse brain[J].Proc Natl Acad Sci U S A,1993,90:6736-6740.
[8]Park SW,Shen X,Tien LT,et al.Methamphetamine-induced changes in the striatal dopamine pathway in mu-opioid receptor knockout mice[J].J Biomed Sci,2011,18:83.
[9]Reinscheid RK,Nothacker HP,Bourson A,et al.Orphanin FQ:a neuropeptide that activates an opioidlike G protein-coupled receptor[J].Science,1995,270:792-794.
[10]Lawrence DM,El-Hamouly W,Archer S,et al.Identification of kappa opioid receptors in the immune system by indirect immunofluorescence[J].Proc Natl Acad Sci U S A,1995,92:1062-1066.
[11]Tao R,Auerbach SB.Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain[J].Neuroscience,1995,68:553-561.
[12]Anraku T,Ikegaya Y,Matsuki N,et al.Withdrawal from chronic morphine administration causes prolonged enhancement of immobility in rat forced swimming test[J].Psychopharmacology(Berl),2001,157:217-220.
[13]Land BB,Bruchas MR,Schattauer S,et al.Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking[J].Proc Natl Acad Sci U S A,2009,106:19168-19173.
[14]Rossetti ZL,Longu G,Mercuro G,et al.Extraneuronal noradrenaline in the prefrontal cortex of morphine-dependent rats:tolerance and withdrawal mechanisms[J].Brain Res,1993,609:316-320.
[15]Der-Avakian A,Markou A.The neurobiology of anhedonia and other reward-related deficits[J].Trends Neurosci,2012,35:68-77.
[16]Keedwell PA,Andrew C,Williams SC,et al.The neural correlates of anhedonia in major depressive disorder[J].Biol Psychiatry,2005,58:843-853.
[17]Lutz PE,Kieffer BL.Opioid receptors:distinct roles in mood disorders[J].Trends Neurosci,2013,36:195-206.
[18]Contet C,Kieffer BL,Befort K.Mu opioid receptor:a gateway to drug addiction[J].Curr Opin Neurobiol,2004,14:370-378.
[19]Filliol D,Ghozland S,Chluba J,et al.Mice deficient for delta-and mu-opioid receptors exhibit opposing alterations of emotional responses[J].Nat Genet,2000,25:195-200.
[20]Bowlby J.Attachment and loss:retrospect and prospect[J].Am JOrthopsychiatry,1982,52:664-678.
[21]Moles A,Kieffer BL,D'Amato FR.Deficit in attachment behavior in mice lacking the mu-opioid receptor gene[J].Science,2004,304:1983-1986.
[22]Konig M,Zimmer AM,Steiner H,et al.Pain responses,anxiety and aggression in mice deficient in pre-proenkephalin[J].Nature,1996,383:535-538.
[23]Pradhan AA,Befort K,Nozaki C,et al.The delta opioid receptor:an evolving target for the treatment of brain disorders[J].Trends Pharmacol Sci,2011,32:581-590.
[24]Wee S,Koob GF.The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse[J].Psychopharmacology(Berl),2010,210:121-135.
[25]Knoll AT,Carlezon WJ.Dynorphin,stress,and depression[J].Brain Res,2010,1314:56-73.
[26]LaForge KS,Yuferov V,Kreek MJ.Opioid receptor and peptide gene polymorphisms:potential implications for addictions[J].Eur J Pharmacol,2000,410:249-268.
[27]Song KY,Choi HS,Hwang CK,et al.Differential use of an in-frame translation initiation codon regulates human mu opioid receptor(OPRM1)[J].Cell Mol Life Sci,2009,66:2933-2942.
[28]Wei LN,Loh HH.Transcriptional and epigenetic regulation of opioid receptor genes:present and future[J].Annu Rev Pharmacol Toxicol,2011,51:75-97.
[29]Wang G,Wei LN,Loh HH.Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation:involvement of Sp3 and a methyl-CpG-binding protein,MBD2,in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells[J].J Biol Chem,2003,278:40550-40556.
[30]Wang G,Liu T,Wei LN,et al.DNA methylation-related chromatin modification in the regulation of mouse delta-opioid receptor gene[J].Mol Pharmacol,2005,67:2032-2039.
[31]Hu X,Cao S,Loh HH,et al.Promoter activity of mouse kappa opioid receptor gene in transgenic mouse[J].Brain Res Mol Brain Res,1999,69:35-43.
[32]Lu S,Loh HH,Wei LN.Studies of dual promoters of mouse kappa-opioid receptor gene[J].Mol Pharmacol,1997,52:415-420.
[33]Knothe C,Oertel BG,Ultsch A,et al.Pharmacoepigenetics of the role of DNA methylation in mu-opioid receptor expression in different human brain regions[J].Epigenomics,2016,8:1583-1599.
[34]Lutz PE,Gross JA,Dhir SK,et al.Epigenetic Regulation of the Kappa Opioid Receptor by Child Abuse[J].Biol Psychiatry,2018,84:751-761.
[35]Wachman EM,Hayes MJ,Lester BM,et al.Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome[J].J Pediatr,2014,165:472-478.
[36]Paterson NE,Markou A.Animal models and treatments for addiction and depression co-morbidity[J].Neurotox Res,2007,11:1-32.
[37]Kastin AJ,Scollan EL,Ehrensing RH,et al.Enkephalin and other peptides reduce passiveness[J].Pharmacol Biochem Behav,1978,9:515-519.
[38]Tejedor-Real P,Mico JA,Maldonado R,et al.Effect of mixed(RB38A)and selective(RB 38B)inhibitors of enkephalin degrading enzymes on a model of depression in the rat[J].Biol Psychiatry,1993,34:100-107.
[39]Tejedor-Real P,Mico JA,Maldonado R,et al.Implication of endogenous opioid system in the learned helplessness model of depression[J].Pharmacol Biochem Behav,1995,52:145-152.
[40]Berrocoso E,Ikeda K,Sora I,et al.Active behaviours produced by antidepressants and opioids in the mouse tail suspension test[J].Int JNeuropsychopharmacol,2013,16:151-162.
[41]Goeldner C,Lutz PE,Darcq E,et al.Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine[J].Biol Psychiatry,2011,69:236-244.
[2]Arroll B,Elley CR,Fishman T,et al.Antidepressants versus placebo for depression in primary care[J].Cochrane Database Syst Rev,2009,3:D7954.
[3]Tenore PL.Psychotherapeutic benefits of opioid agonist therapy[J].JAddict Dis,2008,27:49-65.
[4]Machado-Vieira R,Zarate C J.Proof of concept trials in bipolar disorder and major depressive disorder:a translational perspective in the search for improved treatments[J].Depress Anxiety,2011,28:267-281.
[5]Munoa I,Urizar I,Casis L,et al.The epigenetic regulation of the opioid system:new individualized prompt prevention and treatment strategies[J].J Cell Biochem,2015,116:2419-2426.
[6]Evans CJ,Keith DJ,Morrison H,et al.Cloning of a delta opioid receptor by functional expression[J].Science,1992,258:1952-1955.
[7]Yasuda K,Raynor K,Kong H,et al.Cloning and functional comparison of kappa and delta opioid receptors from mouse brain[J].Proc Natl Acad Sci U S A,1993,90:6736-6740.
[8]Park SW,Shen X,Tien LT,et al.Methamphetamine-induced changes in the striatal dopamine pathway in mu-opioid receptor knockout mice[J].J Biomed Sci,2011,18:83.
[9]Reinscheid RK,Nothacker HP,Bourson A,et al.Orphanin FQ:a neuropeptide that activates an opioidlike G protein-coupled receptor[J].Science,1995,270:792-794.
[10]Lawrence DM,El-Hamouly W,Archer S,et al.Identification of kappa opioid receptors in the immune system by indirect immunofluorescence[J].Proc Natl Acad Sci U S A,1995,92:1062-1066.
[11]Tao R,Auerbach SB.Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain[J].Neuroscience,1995,68:553-561.
[12]Anraku T,Ikegaya Y,Matsuki N,et al.Withdrawal from chronic morphine administration causes prolonged enhancement of immobility in rat forced swimming test[J].Psychopharmacology(Berl),2001,157:217-220.
[13]Land BB,Bruchas MR,Schattauer S,et al.Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking[J].Proc Natl Acad Sci U S A,2009,106:19168-19173.
[14]Rossetti ZL,Longu G,Mercuro G,et al.Extraneuronal noradrenaline in the prefrontal cortex of morphine-dependent rats:tolerance and withdrawal mechanisms[J].Brain Res,1993,609:316-320.
[15]Der-Avakian A,Markou A.The neurobiology of anhedonia and other reward-related deficits[J].Trends Neurosci,2012,35:68-77.
[16]Keedwell PA,Andrew C,Williams SC,et al.The neural correlates of anhedonia in major depressive disorder[J].Biol Psychiatry,2005,58:843-853.
[17]Lutz PE,Kieffer BL.Opioid receptors:distinct roles in mood disorders[J].Trends Neurosci,2013,36:195-206.
[18]Contet C,Kieffer BL,Befort K.Mu opioid receptor:a gateway to drug addiction[J].Curr Opin Neurobiol,2004,14:370-378.
[19]Filliol D,Ghozland S,Chluba J,et al.Mice deficient for delta-and mu-opioid receptors exhibit opposing alterations of emotional responses[J].Nat Genet,2000,25:195-200.
[20]Bowlby J.Attachment and loss:retrospect and prospect[J].Am JOrthopsychiatry,1982,52:664-678.
[21]Moles A,Kieffer BL,D'Amato FR.Deficit in attachment behavior in mice lacking the mu-opioid receptor gene[J].Science,2004,304:1983-1986.
[22]Konig M,Zimmer AM,Steiner H,et al.Pain responses,anxiety and aggression in mice deficient in pre-proenkephalin[J].Nature,1996,383:535-538.
[23]Pradhan AA,Befort K,Nozaki C,et al.The delta opioid receptor:an evolving target for the treatment of brain disorders[J].Trends Pharmacol Sci,2011,32:581-590.
[24]Wee S,Koob GF.The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse[J].Psychopharmacology(Berl),2010,210:121-135.
[25]Knoll AT,Carlezon WJ.Dynorphin,stress,and depression[J].Brain Res,2010,1314:56-73.
[26]LaForge KS,Yuferov V,Kreek MJ.Opioid receptor and peptide gene polymorphisms:potential implications for addictions[J].Eur J Pharmacol,2000,410:249-268.
[27]Song KY,Choi HS,Hwang CK,et al.Differential use of an in-frame translation initiation codon regulates human mu opioid receptor(OPRM1)[J].Cell Mol Life Sci,2009,66:2933-2942.
[28]Wei LN,Loh HH.Transcriptional and epigenetic regulation of opioid receptor genes:present and future[J].Annu Rev Pharmacol Toxicol,2011,51:75-97.
[29]Wang G,Wei LN,Loh HH.Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation:involvement of Sp3 and a methyl-CpG-binding protein,MBD2,in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells[J].J Biol Chem,2003,278:40550-40556.
[30]Wang G,Liu T,Wei LN,et al.DNA methylation-related chromatin modification in the regulation of mouse delta-opioid receptor gene[J].Mol Pharmacol,2005,67:2032-2039.
[31]Hu X,Cao S,Loh HH,et al.Promoter activity of mouse kappa opioid receptor gene in transgenic mouse[J].Brain Res Mol Brain Res,1999,69:35-43.
[32]Lu S,Loh HH,Wei LN.Studies of dual promoters of mouse kappa-opioid receptor gene[J].Mol Pharmacol,1997,52:415-420.
[33]Knothe C,Oertel BG,Ultsch A,et al.Pharmacoepigenetics of the role of DNA methylation in mu-opioid receptor expression in different human brain regions[J].Epigenomics,2016,8:1583-1599.
[34]Lutz PE,Gross JA,Dhir SK,et al.Epigenetic Regulation of the Kappa Opioid Receptor by Child Abuse[J].Biol Psychiatry,2018,84:751-761.
[35]Wachman EM,Hayes MJ,Lester BM,et al.Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome[J].J Pediatr,2014,165:472-478.
[36]Paterson NE,Markou A.Animal models and treatments for addiction and depression co-morbidity[J].Neurotox Res,2007,11:1-32.
[37]Kastin AJ,Scollan EL,Ehrensing RH,et al.Enkephalin and other peptides reduce passiveness[J].Pharmacol Biochem Behav,1978,9:515-519.
[38]Tejedor-Real P,Mico JA,Maldonado R,et al.Effect of mixed(RB38A)and selective(RB 38B)inhibitors of enkephalin degrading enzymes on a model of depression in the rat[J].Biol Psychiatry,1993,34:100-107.
[39]Tejedor-Real P,Mico JA,Maldonado R,et al.Implication of endogenous opioid system in the learned helplessness model of depression[J].Pharmacol Biochem Behav,1995,52:145-152.
[40]Berrocoso E,Ikeda K,Sora I,et al.Active behaviours produced by antidepressants and opioids in the mouse tail suspension test[J].Int JNeuropsychopharmacol,2013,16:151-162.
[41]Goeldner C,Lutz PE,Darcq E,et al.Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine[J].Biol Psychiatry,2011,69:236-244.